

1 Title page- Effectiveness of vaccination against SARS-CoV-2 Omicron variant infection, symptomatic disease,  
2 and hospitalisation: a systematic review and meta-analysis.

3

4 Angela Meggiolaro, MD 1, M. Sane Schepisi, MD 1, Sara Farina, MD 2, Carolina Castagna, MD 2, Alessia  
5 Mammone, PhD 1, Andrea Siddu, MD 1, Paola Stefanelli, PhD 3, Stefania Boccia, PhD 2,4, Giovanni Rezza, MD  
6 1.

7

8 1 General Directorate for Health Prevention, Italian Ministry of Health, Viale Ribotta 5, 00144 Rome, Italy.

9 2 Department of Life Sciences and Public Health, Section of Hygiene, Università Cattolica del Sacro Cuore,  
10 00168 Rome, Italy.

11 3 Department of Infectious Diseases, Istituto Superiore di Sanità, Viale Regina Elena 299,00161, Rome, Italy.

12 4 Department of Woman and Child Health and Public Health-Public Health Area, Fondazione Policlinico  
13 Universitario A. Gemelli IRCCS, 00168 Rome, Italy.

14

15 Corresponding Author: Angela Meggiolaro, General Directorate for Health Prevention, Ministry of Health, Italy,  
16 Viale Giorgio Ribotta, 5 - 00144 – Rome, [a.meggiolaro@sanita.it](mailto:a.meggiolaro@sanita.it), Phone: +390659943789

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

17 **Abstract**

18 **Background**

19 The rapid rise of Sars-Cov2 B.1.1.529 variant (named Omicron) in the late November 2021 prompted the health  
20 authorities to estimate the potential impact on the existing countermeasures, including vaccines. This meta-  
21 analysis aims to assess the effectiveness of the current Sars-Cov2 vaccine regimens against laboratory-  
22 confirmed Omicron infection. A secondary endpoint aims to investigate the waning effectiveness of primary  
23 vaccination against symptomatic Omicron infection and related hospitalization.

24 **Methods**

25 The systematic review started on December 1, 2021 and was concluded on March 1, 2022. Random-effects  
26 (RE) frequentist meta-analyses are performed to estimate the primary vaccination course and the booster  
27 dose effectiveness against Omicron. Multiple meta-regressions are performed under mixed-effects model.  
28 This study is registered with PROSPERO, CRD42021240143.

29 **Findings**

30 In total, 15 out of 502 records are included in the quantitative synthesis. The meta-analysis on B.1.1.529  
31 infection risk produces an OR=0.69 (95%CI: 0.57 to 0.83;  $\tau^2=0.225$ ;  $I^2=99.49\%$ ) after primary vaccination and  
32 an OR=0.30 (95%CI: 0.23 to 0.39;  $\tau^2=0.469$ ;  $I^2=99.33\%$ ) after one additional booster dose. According to the  
33 multiple meta-regression models, one booster dose significantly decreases by 69% the risk of symptomatic  
34 Omicron infection (OR=0.31; 95%CI: 0.23 to 0.40) and by 88% the risk of hospitalization (OR=0.12; 95%CI: 0.08  
35 to 0.19) with respect to unvaccinated. Six months after primary vaccination, the average risk reduction declines  
36 to 22% (OR=0.78; 95%CI: 0.69 to 0.88) against symptomatic infection and to 55% against hospitalization  
37 (OR=0.45; 95%CI: 0.30 to 0.68).

38 **Interpretation**

39 Despite the high heterogeneity, this study confirms that primary vaccination does not provide sufficient  
40 protection against symptomatic Omicron infection. Although the effectiveness of the primary vaccination  
41 against hospitalization due to Omicron remains significantly above 50% after 3 months, it dramatically fades

42 after 6 months. Therefore, the administration of one additional booster dose is recommended within 6 months  
43 and provides a 76% decrease in the odds of symptomatic Omicron after five months.

44 **Funding:** There was no funding source for this study.

#### 45 **KEYWORDS**

46 booster dose - Sars-Cov2 vaccine - effectiveness - Omicron VOC Sars-Cov2 vaccine - symptomatic Omicron  
47 infection - risk of hospitalization – waning immunity

#### 48 **ARTICLE HIGHLIGHTS**

49● the primary vaccination decreases the risk of Omicron infection by 31%, while one additional booster dose  
50 decreases the risk by 70%

51● the primary vaccination course reduces the risk of symptomatic Omicron infection by 24% and the risk of  
52 hospitalization by 50%

53● one additional booster dose decreases by 69% the risk of symptomatic Omicron infection and the risk of  
54 hospitalization by 88%

55● the effectiveness of the primary vaccination against hospitalization dramatically wanes after 3 months from  
56 vaccination, reaching a minimum of 45% in risk reduction after more than 6 months

#### 57 **PANEL: research in context**

##### 58 **Evidence before this study**

59 Omicron variant’s higher transmissibility combined with an increased risk of infection among individuals  
60 vaccinated with primary vaccination have prompted health authorities to introduce a booster vaccination. The  
61 systematic review including “vaccine effectiveness”, “Covid-19”, “SARS-CoV-2”, and “Omicron” search terms,  
62 is performed over three web engines and one early stage research platform (i.e., WHO COVID-19 DATABASE,  
63 PubMed, medRxiv + bioRxiv) Additionally, all relevant web sources reporting living data on vaccine  
64 effectiveness (i.e., <https://view-hub.org/covid-19/> and <https://covid-nma.com/>), electronic databases and  
65 grey literature are considered. The last search update was on March 1, 2022. No country, language, study  
66 design restrictions are applied.

##### 67 **Added value of this study**

- 68 Primary vaccination provides relatively low protection against the Omicron VOC, while one additional booster  
69 dose decreased substantially the risk of symptomatic Omicron infection and of hospitalization.
- 70 **Implications of all the available evidence**
- 71 The booster dose should be recommended after three months and no later than six months after the primary  
72 course vaccination, in order to avoid severe consequences, in particular among the elderly population.

## 73 Introduction

74 On 26 November 2021, WHO designated the variant B.1.1.529 (named Omicron) as a variant of concern.

75 (1)[WHO 1] The global epidemiology of SARS-CoV-2 has been characterized by the rapid spreading of the  
76 Omicron variant (B.1.1.529) ever since and Omicron has become the dominant variant circulating globally.

77 (1)[GISAID] To date, Omicron encompasses several sub lineages, the most common ones are BA.1, BA.1.1 and  
78 BA.2.

79 The SARS-CoV-2 Omicron variant contains several important mutations on the spike protein, potentially  
80 leading to deleterious consequences. The increased transmissibility of Omicron is determined by a  
81 combination of: i) intrinsic biological properties that make the virus more infectious than previous lineages  
82 (e.g. ACE2 receptor binding efficiency or viral replication efficiency) (2)(3)[Peacock, Abdelnabi]; and ii) immune  
83 escape properties resulting in more breakthrough infections among vaccinated or more reinfections among  
84 recovered individuals.(4) (5)[Viana, Yang]

85 Regarding the clinical severity, a less severe onset, lower hospital admission rates and/or shorter length of  
86 hospital stay, as well as declining case fatality rates have been extensively documented by the scientific  
87 literature.(6) (7)(8)(9)[Ferguson, Bager, Lewnard, Nyberg]

88 COVID-19 vaccines licensed in the EU have proven highly effective in preventing SARS-CoV-2 infections (10)  
89 (11)(12)(13)(14)[Hayawi, Harder, Liu, Kow, Pormohammad], however, several in vitro studies suggest a  
90 reduction in neutralizing titres against Omicron in individuals who have received vaccination with two or three  
91 doses and in those who have had prior SARS-CoV-2 infection.(15) (16)(17)[Cele, Wilhelm, Schmidt] Clinical  
92 studies have suggested that the levels of antibodies after BNT162b2, mRNA-1273 and Ad26.COVS vaccines  
93 could last for at least 6 months and decrease over time thereafter. (18)(19)(20)[Barouch, Doria-Rose, Naaber]

94 Nonetheless, recent findings on cross-neutralizing immunity against Omicron among individuals that received  
95 a third dose of mRNA vaccine suggest that the current vaccine regimens may still overcome evasion of humoral  
96 immunity.(21)[Garcia-Beltran]

97 Omicron variant's higher transmissibility combined with an increased risk of infection among vaccinated  
98 individuals, has prompted health authorities to consider the introduction of a booster dose. (22)[Eroglu]

99 Therefore, estimating whether and how Sars-Cov2 primary vaccination effectiveness fades over time is  
100 essential to pinpoint the optimal timing for the booster dose.

101 The objective of this meta-analysis is twofold: first, to assess Sars-Cov2 vaccine effectiveness against infection,  
102 symptomatic disease, and hospitalization due to laboratory-confirmed SARS-CoV-2 Omicron variant. Second,  
103 to investigate the waning effectiveness of the primary course vaccination against Omicron over time.

## 104 **Methods**

### 105 **Search strategy and selection criteria**

106 This systematic review, with meta-analysis, is based on a web search updated weekly until March 1, 2022  
107 **(Table S1, Supplementary material)**. The sources of information essentially consist of three web engines,  
108 including early stage research platforms (i.e., WHO COVID-19 DATABASE, PubMed, medRxiv + bioRxiv), all  
109 relevant web resources reporting living data on vaccine effectiveness (i.e., <https://view-hub.org/covid-19/> and  
110 <https://covid-nma.com/>), electronic databases, and grey literature. Reviews and their references are  
111 examined for inclusion. No country, language, study design restrictions are applied.

112 All the relevant records are screened by title and abstract. Potentially relevant publications undergo full-text  
113 examination disagreements on eligibility are solved through discussion by all the authors. The full texts suitable  
114 for the quantitative synthesis are collected in an excel database for the data extraction. The items for data  
115 extraction are predefined and agreed upon by all authors. The systematic review and meta-analyses are  
116 performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses  
117 (PRISMA) 2020 Statement guidelines. (23) **[Page]** (PRISMA checklist: Supplement 1) This study is registered  
118 with PROSPERO, CRD42021240143. (<https://www.crd.york.ac.uk/PROSPERO/>)

### 119 **Data extraction**

120 Data extracted by at least three out of five independent investigators are collected in Excel tables. The  
121 information drawn up from each full text include:

- 122 1. General characteristics of the study: design, year of publication, country, mean age of the sample,  
123 follow-up, risk of bias;

124 2. Exposure: data are stratified according to Sars-Cov2 vaccination course, hence, two main groups are  
125 acknowledged, corresponding to primary vaccination and one additional booster dose recipients. Within each  
126 subgroup, the vaccination course is classified according to the vaccine type (ChAdOx1 nCoV-19, Ad26.COVS, S,  
127 BNT162b2, or mRNA-1273 vaccine). Heterologous primary schedules are included. All SARS-CoV-2 vaccine  
128 recipients are considered as *exposed*, while unvaccinated are considered as *unexposed*.

129 3. Outcome: cases are defined as being due to the Omicron variant, based on S target–negative results  
130 on PCR or whole-genome sequencing. Regardless the vaccine course undertaken, cases occurred within 14  
131 days after the primary vaccination or within one week from the booster administration are not included.  
132 Omicron cases are classified by clinical severity into any Sars-Cov2 infection excluding hospitalization,  
133 symptomatic disease and hospitalization due to COVID-19 disease.

134 4. Risk of bias: ROBINS-I (risk of bias in non-randomized studies of interventions) is applied to assess risk  
135 of bias. The tool classifies the risk into “low”, “moderate” and “serious”. (24)[Sterne]

#### 136 Endpoints

137 The primary endpoint aims to assess the overall effectiveness of the current Sars-Cov2 vaccination regimens  
138 against Omicron. Study results are stratified by clinical severity and reported at the maximum follow-up and.  
139 The secondary endpoint attempts to measure the waning effectiveness of the primary vaccination at  
140 consecutive time intervals. In particular, VE is assessed in intervals of 3, 6, and more than 6 months after the  
141 last dose.

142 The point estimates of the effect size, as measured by Log odds ratios (Log ORs) and 95% confidence interval  
143 (95%CI), are computed through meta-analysis and converted to ORs by exponentiation. VE is quantified as the  
144 risk reduction of any infection event, expressed as a percentage, compared to the unvaccinated group.

#### 145 Statistical analysis

146 A random-effects (RE) model employing inverse variance method (IV) is fitted to the data. The amount of  
147 heterogeneity (i.e.,  $\tau^2$ ), is estimated using the restricted maximum-likelihood estimator. (25)[Viechtbauer] In  
148 addition to the estimate of  $\tau^2$ , the QQ-test for heterogeneity (26)[Cochran] and the  $I^2$  statistic (27)[Higgins] are  
149 reported. Studentized residuals and Cook’s distances are used to examine whether studies may be outliers

150 and/or influential in the context of the model. The normality assumption is evaluated via QQ normal  
151 plot. (28)[Viechtbauer 2]

152 The publication bias is evaluated through a funnel plot and tested via regression test (weighted regression  
153 with multiplicative dispersion). The rank correlation test (29,30)[Begg] and the regression test (30)[Sterne 2],  
154 using the standard error of the observed outcomes as predictor, are used to check for funnel plot asymmetry.  
155 Regarding the primary vaccination waning effectiveness, the subgroup meta-analyses include the stratification  
156 by time intervals since the last dose uptake for symptomatic Covid-19 risk and hospitalization risk due to Sars-  
157 Cov2 infection. Studies providing vaccine effectiveness estimates at discrete time intervals after the primary  
158 vaccination course, which met the predefined screening criteria, underwent further meta-analysis and meta-  
159 regression. In order to test for subgroup differences, both a mixed effect meta-regression model assuming a  
160 common  $\tau^2$  value within the subgroups and a three level meta-regression model, allowing for different  $\tau^2$  values  
161 across subgroups, are fitted.

162 Finally, in order to examine whether one or multiple moderator variables are able to account for the  
163 heterogeneity (or part of it), multiple meta-regressions are performed under the mixed-effects model for both  
164 continuous and nominal study level covariates.(25)[Viechtbauer 2005] The analysis is carried out using R  
165 (version 4.0.5).

#### 166 Role of the funding source

167 There was no funding source for this study.

## 168 Results

169 The web search provided 502 unduplicated records. **(Figure 1)** In total, 15 studies and 55 observations are  
170 included in the quantitative synthesis concerning the overall Sars-Cov2 vaccine effectiveness against Omicron  
171 VOC. All of them have a test-negative case-control design except one cohort study. (31)[Spensley] **(Table S2,**  
172 **Supplementary material)**. The majority of the studies are carried out in US and UK (59%), the sample age is on  
173 average 45 years, while the induction period for immunization appears slightly shorter for studies analysing  
174 the effectiveness of the booster dose compared to those investigating the primary course vaccination (on  
175 average 11 and 16 days since administration, respectively). The 75% of the observations concern the mRNA



176 vaccine effectiveness, while the 13% involve heterologous vaccine regimens. The booster dose is administered  
177 on average 6 months after the primary course (**Table S1, Supplementary material 2**). The majority of the  
178 selected studies involves the general population, while **Gray et al.** report results on HCWs (32)[**Gray**] and  
179 **Spensley et al.** on patients affected by end stage kidney disease receiving in hospital haemodialysis.  
180 (31)[**Spensley**] All the studies examine the VE of mRNA BNT162b2 vaccine except Tseng et al. and Gray et al.  
181 which investigate mRNA-1273 and aAd26.COV.2 effectiveness, respectively. (33)(32)[**Tseng**] [**Gray**]  
182 Five studies report data on the waning effectiveness of the primary vaccination against symptomatic Omicron  
183 infection. (34)(35,36)(36)(37)(38)[**Accorsi, Andeweg, Chemaitelly, Powell, Sheikh**] A considerable effectiveness  
184 rebound after mRNA booster dose is shown by 4 studies.(34)(35)(36)(38)[**Accorsi, Andeweg, Chemaitelli,**  
185 **Sheikh**] VE against hospitalisation caused by Omicron is analysed by seven studies. (32)(33)(36)(39)(40)(41)  
186 (42)[**Gray, Tseng, Chemaitelly, Collie, Ferdinands, Gray, Tartof, Thompson**]

187

188

189

190

191

192

193

194

195

196


197

198

199

200

201



221 Figure 1. Prisma flow diagram

223 *Risk of Omicron infection after primary course vaccination*

224 A total of 14 studies and k=27 observations are included in this meta-analysis. The median follow-up period is  
 225 213 days (70-365). The observed log odds ratios range from -1.275 to 0.467, with the majority of estimates  
 226 being negative (67%). The estimated average log odds ratio based on the RE model is  $\hat{\mu} = -0.3788$  (95% CI:  
 227 -0.568 to -0.190). The values are transformed into the odds ratio scale through exponentiation, such that OR=

228  $\exp(\hat{\mu}) = 0.685$  (95%CI: 0.567 to 0.827). The average outcome differs significantly from zero ( $z = -3.931$ ,  
229  $p < 0.0001$ ). Hence, the result suggests that the risk of Sars-Cov2 infection in vaccinated individuals is on average  
230 31.5% lower than the infection risk in unvaccinated. The forest plot is exhibited in. According to the Q-test,  
231 the true outcomes appear to be heterogeneous ( $Q(26) = 1962.9$ ,  $p < 0.0001$ ;  $\tau^2 = 0.225$ ;  $I^2 = 99.49\%$ ). Neither the  
232 rank correlation nor the Egger's regression test indicate any funnel plot asymmetry ( $p = 0.901$  and  $p = 0.409$ ,  
233 respectively). The analysis of heterogeneity is displayed in **Figures S1-S5 (Supplementary material)**.

234 The subgroup analysis includes five subgroups, three of them display significant results ( $p < 0.05$ ). Regarding  
235 the vaccines used for the primary vaccination, only messenger RNA (mRNA) vaccine exhibits a significant  
236  $OR = 0.62$  (95%CI: 0.51 to 0.76). (**Figure S11, Supplementary material**). The stratified meta-analysis assessing the  
237 primary vaccination effectiveness against Omicron VOC by severity of symptoms includes three subgroups and  
238 the test for subgroup differences is significant ( $Q_M(df = 2) = 23.30$ ,  $p < 0.0001$ ) (**Figure 2**). According to the  
239 three level meta-analysis, the 35.6% of the total variance is distributed within effect sizes (second level), whilst  
240 the 64.1% is distributed between groups (third level). The multiple meta-regression embeds four moderators:  
241 risk of bias, mean age of the samples (variable centred on the overall mean value of 45 years), vaccine  
242 employed in the primary course vaccination (viral vector vaccine or 'VV', mRNA and heterologous vaccination  
243 with both VV and mRNA or 'VV/mRNA'). Albeit reduced, the residual heterogeneity remains significant ( $QE$   
244 ( $df = 19$ ) = 448.6,  $p < 0.0001$ );  $\tau^2 = 0.0701$ ;  $I^2 = 97.25\%$ ). The  $(0.2254 - 0.0701) / 0.2254 = 68.9\%$  of the total amount  
245 of heterogeneity can be explained by including four moderators in the meta-regression, suggesting further  
246 unobserved effect not captured by the model. On average, the risk of symptomatic Covid-19 appears 24%  
247 lower for the vaccinated group compared to the unvaccinated ( $OR = 0.76$ ; 95%CI: 0.58 to 0.99), while the risk  
248 of hospitalization is 50% lower for the vaccinated group ( $OR = 0.50$ ; 95%CI: 0.34 to 0.72). The OR estimate for  
249 any positive rt-PCR is not significant. (**Figure S13 and Table S4, Supplementary material**).

#### 250 *Risk of Omicron infection after one booster dose*

251 A total of  $k = 28$  observations and 13 studies are included in this meta-analysis. The median follow-up is 62 days  
252 (14-150). All the studies investigate the effectiveness of mRNA booster dose except 'Gray', which  
253 demonstrates the efficacy of a two-dose regimen of Ad26.COV.2 vaccine.(32) [**Gray**] The observed log odds

254 ratios range from  $-2.5194$  to  $-0.0550$ , with the 100% of estimates being negative. The average log odds ratio  
255 based on the RE model is  $\hat{\mu} = -1.2157$  (95%CI:  $-1.4854$  to  $-0.9460$ ). Therefore, the outcome differs significantly  
256 from zero ( $z = -8.8351$ ,  $p < 0.0001$ ). The exponentiation yields an average OR =  $0.296$  (95%CI:  $0.226$  to  $0.388$ ),  
257 hence, vaccinated with one booster dose have a 70.4% risk reduction of Omicron infection compared to  
258 unvaccinated. According to the Q-test, the true outcomes appear to be heterogeneous ( $Q(27) = 4624.51$ ,  
259  $p < 0.0001$ ;  $\tau^2 = 0.4686$ ;  $I^2 = 99.33\%$ ). The influential analysis does not detect overly influential outliers. **(Figure S6-**  
260 **S10, Supplementary material)**. There is no indication of publication bias because neither the rank correlation  
261 nor the regression test indicates any funnel plot asymmetry ( $p = 0.7992$  and  $p = 0.0735$ , respectively). The  
262 subgroup analysis includes six subgroups, four of them display significant results ( $p < 0.05$ ). Notably, the risk  
263 reduction for the booster group seems 69% lower in studies reporting results at 3 months of follow-up (OR =  
264  $0.31$ ; 95%CI:  $0.23$  to  $0.42$ ) and 76% in studies reporting 5 months follow-up (OR =  $0.24$ ; 95%CI:  $0.12$  to  $0.428$ )  
265 at most. However, the test for interaction is not significant **(Figure S12, Supplementary material)**.


266 The stratified meta-analysis on one booster effectiveness against Omicron VOC by clinical severity includes  
267 three subgroups **(Figure 2b)**. The test for subgroup differences is significant (QM (df=2) =  $10.88$ ,  $p = 0.004$ ).  
268 According to the multilevel meta-analysis approach, the 57.3% of the total variance is distributed within effect  
269 sizes at second level, whilst the 42.2% is distributed between groups (level 3).

270 The multiple meta-regression model includes four moderators: risk of bias, mean age of the samples (centred  
271 on the overall mean value of  $44.43$  years), regimen of the primary course vaccination ('VV', mRNA,  
272 'VV/mRNA'). As expected, the residual heterogeneity slightly decreases but remains significant (QE (df = 20)  
273 =  $306.9$ ,  $p < 0.0001$ ;  $\tau^2 = 0.1037$ ;  $I^2 = 94.54\%$ ) suggesting further unobserved effect not captured by the predictors  
274 in the model. Overall, the multiple meta-regression can explain the 77.9% of the total amount of  
275 heterogeneity. On average, the risk of symptomatic Covid-19 appears, 69% lower for the booster group  
276 compared to the unvaccinated (OR =  $0.31$ ; 95%CI:  $0.23$  to  $0.40$ ), whilst the risk of hospitalization is on average  
277 88% lower (OR =  $0.12$ ; 95%CI:  $0.08$  to  $0.19$ ) **(Figure S14 and Table S4, Supplementary material)**.


278

279

**a) Stratified forest plot: Covid-19 risk by severity of infection after primary vaccination**



**b) Stratified forest plot: Covid-19 risk by severity of infection after one booster**



280

281

282

283

284

285

286


287

**Figure 2. Stratified forest plots and subgroup meta-analyses.** Random effect model, IV method. (a) Effectiveness of primary course vaccination, by severity of symptoms. The risk of symptomatic Covid-19 is assessed by 12 observations, the risk of hospitalization by seven and the risk of any positive rt-PCR by eight. The test for subgroup difference is significant (QM (df=2) =23.3, p<0.0001). According to the subgroup analysis, the risk of any positive rt-PCR appears 7% higher among the vaccinated group with respect to the unvaccinated, however, the result is not significant (OR= 1.07; 95%CI: 0.82 to 1.40). The risk reduction for symptomatic Covid-19 is 32% lower among the vaccinated group compared to the unvaccinated (OR=0.68; 95%CI: 0.54 to 0.85). Regarding hospitalization due to Omicron infection, the risk appears 58% lower for the vaccinated group compared to unvaccinated (OR= 0.42; 95%CI: 0.35 to 0.49). (b) Effectiveness of one booster dose against Omicron VOC, by severity of symptoms. The effectiveness of one booster

288 dose is estimated by 12 observations for the symptomatic Covid-19, by seven for hospitalization risk and by nine for any positive rt-PCR. The test for  
 289 subgroup difference is significant (QM (df =2) =10.88, p<0.0001). The risk of positive rt-PCR appears 57% lower among the booster group with respect  
 290 to the unvaccinated group (OR=0.43; 95%CI: 0.31 to 0.60). The risk reduction in favour of the booster group is 68% for symptomatic Covid-19 (OR=0.32;  
 291 95%CI: 0.21 to 0.48) and 86% for hospitalization (OR=0.14; 95%CI: 0.10 to 0.20).

292

293



294

295 **Figure 3. Meta-regression model estimates, risk of Omicron infection by severity of symptoms: OR [95%CI] estimates from meta-regression with one**  
 296 **moderator (a) and multiple moderator (b).** In the restricted meta-regression (one moderator), the risk of any positive rt-PCR appears 7% higher among  
 297 the primary vaccination group with respect to unvaccinated (OR= 1.07; 95%CI: 0.83 to 1.39); whilst in the multiple meta-regression, the risk of any  
 298 positive rt-PCR appears nearly 30% higher for primary vaccination. However, the results are not significant (OR= 1.302; 95%CI: 0.894 to 1.898).

299 *Waning effectiveness of Sars-Cov2 primary vaccination against Omicron VOC*

300 Overall, eight studies assess the effectiveness of the primary vaccination against Sars-Cov2 at consecutive time  
 301 intervals. The time intervals correspond to three months, three to six months, six months and longer than six  
 302 months since the last dose administration. Therefore, the stratified meta-analyses on Sars-Cov2 vaccine  
 303 waning effectiveness against Omicron include four subgroups. **(Figure 4)** The risk of developing a symptomatic  
 304 Covid-19 is investigated by seven studies and the risk of hospitalization is investigated by four studies (Table  
 305 S5, Supplementary material) Only in 33% of cases, Omicron rt-PCR positivity is tested routinely, therefore, it is  
 306 not possible to consistently estimate the vaccine effectiveness in preventing Sars-Cov2 infection, as well as the  
 307 vaccine's capability of limiting the virus spreading.

308 Concerning the risk of symptomatic Omicron infection after vaccination with primary course, a total of  $k=29$   
309 observations are included in the meta-analysis; all estimates are based on the RE model. The overall Log odds  
310 ratio based on the RE model is  $\hat{\mu}=-0.4792$  (95% CI:  $-0.6418$  to  $-0.3165$ ), equivalent to  $OR=0.62$  (95%CI= $0.53-$   
311  $0.73$ ) after exponentiation. The outcomes appear heterogeneous ( $Q(28)=1394.37$ ,  $p<0.0001$ ;  $\tau^2=0.1773$ ;  
312  $I^2=99.01\%$ ) and the regression test indicates funnel plot asymmetry ( $p<0.0001$ ), however, the rank correlation  
313 test is not significant ( $p=0.3051$ ) (**Figure S17a, Supplementary material**). The test for subgroup differences is  
314 not statistically significant ( $Q_M(df=3)=4.169$ ,  $p=0.2438$ ) (**Figure 4a**). According to the multilevel meta-analysis,  
315 the 93.1% of the total variance is distributed at second level ( $\sigma^2=0.168$ ) while the 5.9% is distributed at third  
316 level (between groups).

317 The multiple meta-regression model includes four moderators: time-lapse since the last dose, risk of bias, age  
318 of the study (variable centred on the mean value of 41.4), vaccine technology (VV, mRNA, heterologous  
319 vaccination or VV/mRNA). The residual heterogeneity notably decreases but remains significant ( $QE(df=20)=$   
320  $53.6$ ,  $p<0.0001$ ;  $\tau^2=0.0042$ ;  $I^2=65.10\%$ ). The average risk reduction is 46% for vaccinated with respect to  
321 unvaccinated ( $OR=0.54$ ; 95%CI:  $0.48$  to  $0.61$ ) within 3 months, 22% within 6 months ( $OR=0.78$ ; 95%CI:  $0.69$  to  
322  $0.88$ ) and 16% between 3 and 6 months ( $OR=0.84$ ; 95%CI:  $0.74$  to  $0.96$ ). Moreover, the OR decreases on  
323 average by 2% in studies where the mean age is one more unit away from the overall mean of 41.4 years  
324 ( $OR=0.98$ ; 95%CI:  $0.98$  to  $0.99$ ). The heterologous vaccination (VV/mRNA) provides a positive coefficient and  
325 an 18% higher risk of symptomatic Omicron infection with respect to mRNA vaccine regimens ( $OR=1.18$ ;  
326 95%CI:  $1.08$  to  $1.29$ ) (**Figure S20 and Table S6, Supplementary material**).


327 The meta-analysis on Sars-Cov2 primary vaccination effectiveness against hospitalization embeds a total of 4  
328 studies and 11 observations (**Figure 4b**). The average log odds ratio based on the RE model is  $\hat{\mu}=-0.8634$   
329 (95%CI:  $-1.0348$  to  $-0.6920$ ), which corresponds to  $OR=0.42$  (95%CI:  $0.36$  to  $0.50$ ) by exponentiation.  
330 According to the Q-test, the true outcomes appear heterogeneous ( $Q(10)=36.38$ ,  $p<0.0001$ ;  $\tau^2=0.051$ ;  
331  $I^2=73.3\%$ ). The regression test indicates funnel plot asymmetry ( $p=0.0272$ ); however it is not confirmed by the  
332 rank correlation test ( $p=0.542$ ) (**Figure S17, Supplementary material**). The test for subgroup differences  
333 suggests that there is not a statistically significant subgroup effect ( $Q_M(df=3)=3.9437$ ,  $p=0.268$ ). The three

334 level meta-analysis approach shows that the 73.3% of the total variance is distributed at second level  
 335 ( $\sigma^2=0.051$ ) while  $\sigma^2=0.00$  at third level.

336 In the multiple meta-regression model, only three predictors are designated as moderators because ‘vaccine  
 337 regimen’ contains only observations on mRNA vaccines. The estimated amount of residual heterogeneity is  
 338  $\tau^2=0.00$  and the test for residual heterogeneity is no longer significant (QE (df =4) =1.83, p=0.766). All  
 339 moderators exhibit significant coefficients except ‘risk of bias’. The adjusted average effect corresponds to an  
 340 OR=0.28 (95%CI= 0.21 to 0.38) within 3 months and average risk reduction of 72% for vaccinated in  
 341 comparison to unvaccinated. The average OR raises to 0.38 (95%CI: 0.25 to 0.59) within 6 months and to 0.45  
 342 (95%CI: 0.30 to 0.68) after more than 6 months. The variable ‘age’ (centered on the mean of 48.3 years)  
 343 generates a significant coefficient indicating that the risk of hospitalization increases on average by 2.6% by  
 344 increasing of one unit the study mean age (OR=1.026; 95%CI: 1.003 to 1.049) (Figure S21 and Table S6,  
 345 **Supplementary material**). The predicted ORs for symptomatic infection and hospitalization risks are plotted in  
 346 **Figure 5**.

347

a) Stratified forest plot: effectiveness of primary vaccination against symptomatic Covid-19, by time intervals




348

349



**b) Stratified forest plot: effectiveness of primary vaccination against hospitalization risk, by time intervals**




350

351 **Figure 4. Stratified Forest Plots.**

352 The forest plots include four subgroups representing four discrete time intervals. The results of the individual  
 353 studies are grouped together according to the corresponding subgroup. Below each subgroup, a summary  
 354 polygon shows the results of a RE meta-analysis. The pooled effect sizes are expressed as Log Odds Ratios. The  
 355 summary polygon at the bottom of the plot shows the results from the overall RE model (IV method). (a)  
 356 Stratified forest plot, symptomatic Omicron infection risk, by time intervals. According to the subgroup  
 357 analysis, the risk reduction appears to be 50% among vaccinated compared to unvaccinated until 3 months  
 358 (OR=0.50; 95%CI: 0.40 to 0.62). The risk reduction decreases to nearly 41% with respect to unvaccinated within  
 359 6 months (OR=0.59; 95%CI: 0.44-0.78), and to 24% thereafter (OR=0.76; 95%CI: 0.56 to 1.03). (b) Stratified  
 360 forest plot, hospitalization due to Omicron infection risk, by time intervals. The risk reduction appears 65%  
 361 lower among vaccinated compared to unvaccinated within 3 months (OR=0.35; 95%CI: 0.29 to 0.42); whereas  
 362 the overall risk reduction is on average 64% compared to unvaccinated within 6 months (OR=0.36; 95%CI: 0.23  
 363 to 0.56) and 54% thereafter (OR=0.46; 95%CI=0.36 to 0.58). Only one study assesses the risk of hospitalization  
 364 between 3 and 6 months (OR=0.60; 95%CI=0.49 to 0.73) (41)[Tartof]

365



366

367 **Figure 5. Plots displaying the trend of symptomatic Omicron infection and related hospitalization risk.** Y-axes:  
 368 ORs [95%CI] estimates from meta-regression with one moderator (a) and meta-regression with multiple  
 369 moderators (b). The risk of symptomatic Covid-19 infections is depicted in blue while the risk of hospitalization  
 370 in purple. X-axes: time intervals at 3 months, 6 months and over 6 months from last dose administration. Time  
 371 interval running from 3 to 6 months is suppressed because only one study estimate is available for  
 372 hospitalization risk.

### 373 Discussion

374 The evidence achieved through the quantitative synthesis suggests that a primary vaccination course is not  
 375 sufficiently protective against Omicron. In fact, the probabilities of symptomatic infection and related  
 376 hospitalization are nearly 50% for vaccinated with respect to unvaccinated, basing on a maximum follow up of  
 377 one year. One additional booster dose decreases by 69% the risk of symptomatic Omicron infection (OR=0.31;  
 378 95%CI: 0.23 to 0.40) and by 88% the risk of hospitalization (OR=0.12; 95%CI: 0.08 to 0.19) with respect to  
 379 unvaccinated at a maximum follow-up of five months. Albeit not significant, the subgroup analysis does not  
 380 suggest a waning effectiveness of the booster dose after five months, however, the evidence on long term  
 381 effectiveness is still limited.

382 The risk of any positive rt-PCR appears higher among the primary vaccination group with respect to the  
383 unvaccinated (OR= 1.302; 95%CI: 0.89 to 1.90); however, the results are not significant.

384 Age does not appear as a significant predictor, notwithstanding the negative association with the overall risk  
385 of infection after the primary vaccination and after the booster. Conversely, age is negatively associated with  
386 the risk of symptomatic infection and positively associated with the risk of hospitalization after primary  
387 vaccination. Some unobserved effect of uncontrolled confounding must be acknowledged in interpreting this  
388 association. For instance, the different extent to which the joint effect of the mitigation measures uplift has  
389 affected the younger and the elderly population. However, despite the generalizability, these results do not  
390 allow to infer any clear conclusion.

391 There is no clear advantage between homologous and heterologous vaccination, particularly on boosting,  
392 probably because the majority of the appraisals have been conducted on mRNA vaccination and data on  
393 heterologous vaccination are quite sparse.

394 As the administration of booster doses, whether homologous or heterologous, should take into consideration  
395 the waning protection of the primary course and the optimal interval for an efficient immune response, the  
396 implications of our findings extend to health care and public health policy.

397 Our results on the waning trends align with the estimates provided by the clinical trials. (43)(44)(45)[**Polack,**  
398 **Baden, Sadoff]** According to our estimates, the effectiveness of primary vaccination against Omicron reaches  
399 a peak within three months determining a risk reduction of roughly 72% with respect to unvaccinated. The  
400 protection is maintained at six months, with risk reduction of nearly 62%, and dramatically decline thereafter  
401 (55% less probabilities for vaccinated compared to unvaccinated). Overall, the effectiveness against  
402 hospitalization diminishes by approximately 10-15% every three months, and the point estimates show wide  
403 confidence intervals. (46)[**Lin]**

404 The ramping-up trend for symptomatic Omicron infection risk appears steeper than the trend for  
405 hospitalization risk; in other words, the protection against the symptomatic Covid-19 declines faster. The risk  
406 reduction of symptomatic Omicron infection after a primary vaccination declines sharply to 22% in six months.

407 Our study provides the best available data synthesis on vaccine effectiveness against Omicron; however,  
408 several limitations must be acknowledged. First, only in 33% of cases, Omicron rt-PCR positivity is tested  
409 routinely, therefore, it is not possible to draw conclusion on vaccine effectiveness in preventing Omicron  
410 infection. Second, by examining periods during which Omicron and Delta coexistence was very likely, early  
411 studies generate a distortion of the VE effectiveness estimate.

412 In part, the high heterogeneity surrounding the meta-analysis estimates stems from the observational design  
413 of the included studies. Unless a randomization process, the meta-regression cannot capture the unobserved  
414 effect of confounders such as the level of community transmission, the implementation of public health  
415 prevention measures, and the surge of new variants. For instance, regarding the Omicron variant definition,  
416 the studies on BA.1 do not distinguish between the different sub-lineages, although the majority of them are  
417 conducted during the BA.1 surge. Differences between BA.2 and BA.1 in evading immunity remain undefined.  
418 In conclusion, despite the high heterogeneity, only in part explained by the meta-regressions, this study  
419 confirms that primary vaccination does not provide sufficient protection against symptomatic Omicron  
420 infection, because the overall effectiveness estimate never reaches a minimum requirement of 50% in risk  
421 reduction. One additional booster dose decreases substantially the risk of symptomatic Omicron infection and  
422 of hospitalization. The booster dose administration should be recommended after three months and no later  
423 than six months following the primary vaccination course.

424

#### 425 **Contributors**

426 Conceptualization, G.R., A.M. and M.S.S.; methodology, M.S.S. and A.M.; formal analysis, A.M.; data curation,  
427 A.M., M.S.S., A.M., C.C., S.F., A.S.; writing—original draft preparation, A.M. and M.S.S.; writing—review and  
428 editing, A.M., C.C., S.B., A.S, P.S. and M.S.S.; supervision, S.B. and G.R. All authors have read and agreed to the  
429 published version of the manuscript.

#### 430 **Declaration of interest**

431 The authors declare no conflict of interest.

#### 432 **Data sharing**

433 Data supporting the reported results are available on request to the Authors.

434

## 435 References

- 436 1. GISAID - hCov19 Variants [Internet]. [cited 2022 Jun 7]. Available from:  
437 <https://www.gisaid.org/hcov19-variants/>
- 438 2. Peacock TP, Brown JC, Zhou J, Thakur N, Newman J, Kugathasan R, et al. The SARS-CoV-2 variant,  
439 Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the  
440 endosomal route of entry. [cited 2022 Jun 7]; Available from:  
441 <https://doi.org/10.1101/2021.12.31.474653>
- 442 3. Abdelnabi R, Foo CS, Zhang X, Lemmens V, Maes P, Slechten B, et al. The omicron (B.1.1.529) SARS-  
443 CoV-2 variant of concern does not readily infect Syrian hamsters. *bioRxiv* [Internet]. 2021 Dec 26  
444 [cited 2022 Jun 7];2021.12.24.474086. Available from:  
445 <https://www.biorxiv.org/content/10.1101/2021.12.24.474086v1>
- 446 4. Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL, et al. Rapid epidemic expansion of  
447 the SARS-CoV-2 Omicron variant in southern Africa. *Nature* [Internet]. 2022 Mar 24 [cited 2022 Jun  
448 7];603(7902):679–86. Available from: <https://pubmed.ncbi.nlm.nih.gov/35042229/>
- 449 5. Yang W, Shaman J. SARS-CoV-2 transmission dynamics in South Africa and epidemiological  
450 characteristics of the Omicron variant. *medRxiv* [Internet]. 2021 Dec 21 [cited 2022 Jun 7]; Available  
451 from: <http://www.ncbi.nlm.nih.gov/pubmed/34981071>
- 452 6. [PDF] Report 50: Hospitalisation risk for Omicron cases in England | Semantic Scholar [Internet].  
453 [cited 2022 Jun 7]. Available from: [https://www.semanticscholar.org/paper/Report-50%3A-  
454 Hospitalisation-risk-for-Omicron-cases-Ferguson-  
455 Ghani/8b696e1a05092a11b39b92b4adea7bc05e7032df](https://www.semanticscholar.org/paper/Report-50%3A-Hospitalisation-risk-for-Omicron-cases-Ferguson-Ghani/8b696e1a05092a11b39b92b4adea7bc05e7032df)
- 456 7. Bager P, Wohlfahrt J, Bhatt S, Edslev SM, Sieber RN, Ingham AC, et al. Reduced Risk of  
457 Hospitalisation Associated With Infection With SARS-CoV-2 Omicron Relative to Delta: A Danish  
458 Cohort Study. *SSRN Electronic Journal* [Internet]. 2022 Jan 20 [cited 2022 Jun 7]; Available from:  
459 <https://papers.ssrn.com/abstract=4008930>
- 460 8. Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes among patients  
461 infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California. [cited 2022 Jun 7];  
462 Available from: <https://doi.org/10.1101/2022.01.11.22269045>
- 463 9. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative analysis of  
464 the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta  
465 (B.1.617.2) variants in England: a cohort study. *The Lancet* [Internet]. 2022 Apr 2 [cited 2022 Jun  
466 7];399(10332):1303–12. Available from:  
467 <http://www.thelancet.com/article/S0140673622004627/fulltext>
- 468 10. Hayawi K, Shahriar S, Serhani MA, Alashwal H, Masud MM. Vaccine versus variants (3Vs): Are the  
469 COVID-19 vaccines effective against the variants? A systematic review. *Vaccines (Basel)*. 2021 Nov  
470 1;9(11).
- 471 11. Harder T, Külper-Schiek W, Reda S, Treskova-Schwarzbach M, Koch J, Vygen-Bonnet S, et al.  
472 Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant:

- 473 second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021.  
474 Euro surveillance : bulletin European sur les maladies transmissibles = European communicable  
475 disease bulletin [Internet]. 2021 Oct 14 [cited 2022 Jun 7];26(41). Available from:  
476 <https://pubmed.ncbi.nlm.nih.gov/34651577/>
- 477 12. Liu Q, Qin C, Liu M, Liu J. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a  
478 systematic review and meta-analysis. *Infectious Diseases of Poverty* [Internet]. 2021 Dec 1 [cited  
479 2022 Jun 7];10(1). Available from: [/pmc/articles/PMC8590867/](https://pubmed.ncbi.nlm.nih.gov/34651577/)
- 480 13. Kow CS, Ramachandram DS, Hasan SS. The effectiveness of mRNA-1273 vaccine against COVID-19  
481 caused by Delta variant: A systematic review and meta-analysis. *J Med Virol* [Internet]. 2022 May 1  
482 [cited 2022 Jun 7];94(5):2269–74. Available from: <https://pubmed.ncbi.nlm.nih.gov/34978339/>
- 483 14. Pormohammad A, Zarei M, Ghorbani S, Mohammadi M, Neshin SAS, Khatami A, et al. Effectiveness  
484 of COVID-19 Vaccines against Delta (B.1.617.2) Variant: A Systematic Review and Meta-Analysis of  
485 Clinical Studies. *Vaccines (Basel)* [Internet]. 2021 Jan 1 [cited 2022 Jun 7];10(1). Available from:  
486 <https://pubmed.ncbi.nlm.nih.gov/35062684/>
- 487 15. Cele S, Jackson L, Khoury DS, Khan K, Moyo-Gwete T, Tegally H, et al. SARS-CoV-2 Omicron has  
488 extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for  
489 infection. *medRxiv* [Internet]. 2021 Dec 17 [cited 2022 Jun 7]; Available from:  
490 <http://www.ncbi.nlm.nih.gov/pubmed/34909788>
- 491 16. Wilhelm A, Widera M, Grikscheit K, Toptan T, Schenk B, Pallas C, et al. Reduced Neutralization of  
492 SARS-CoV-2 Omicron Variant by Vaccine Sera and monoclonal antibodies. *medRxiv* [Internet]. 2021  
493 Dec 8 [cited 2022 Jun 7];2021.12.07.21267432. Available from:  
494 <https://www.medrxiv.org/content/10.1101/2021.12.07.21267432v1>
- 495 17. Schmidt F, Muecksch F, Weisblum Y, Silva J da, Bednarski E, Cho A, et al. Plasma neutralization  
496 properties of the SARS-CoV-2 Omicron variant. *medRxiv* [Internet]. 2021 Dec 13 [cited 2022 Jun  
497 7];2021.12.12.21267646. Available from:  
498 <https://www.medrxiv.org/content/10.1101/2021.12.12.21267646v1>
- 499 18. Barouch DH, Stephenson KE, Sadoff J, Yu J, Chang A, Gebre M, et al. Durable Humoral and Cellular  
500 Immune Responses Following Ad26.COV2.S Vaccination for COVID-19. *medRxiv* [Internet]. 2021 Jul 7  
501 [cited 2022 Jun 8];2021.07.05.21259918. Available from:  
502 <https://www.medrxiv.org/content/10.1101/2021.07.05.21259918v1>
- 503 19. Doria-Rose N, Suthar MS, Makowski M, O'Connell S, McDermott AB, Flach B, et al. Antibody  
504 Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. *N Engl J*  
505 *Med* [Internet]. 2021 Jun 10 [cited 2022 Jun 7];384(23):2259–61. Available from:  
506 <https://pubmed.ncbi.nlm.nih.gov/33822494/>
- 507 20. Naaber P, Tserel L, Kangro K, Sepp E, Jürjenson V, Adamson A, et al. Dynamics of antibody response  
508 to BNT162b2 vaccine after six months: a longitudinal prospective study. *The Lancet regional health*  
509 *Europe* [Internet]. 2021 Nov 1 [cited 2022 Jun 7];10. Available from:  
510 <https://pubmed.ncbi.nlm.nih.gov/34514454/>
- 511 21. Garcia-Beltran WF, st. Denis KJ, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML, et al. mRNA-based  
512 COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. *Cell*  
513 [Internet]. 2022 Feb 3 [cited 2022 Jun 7];185(3):457–466.e4. Available from:  
514 <https://pubmed.ncbi.nlm.nih.gov/34995482/>

- 515 22. Eroglu B, Nuwarda RF, Ramzan I, Kayser V. A Narrative Review of COVID-19 Vaccines. *Vaccines*  
516 (Basel) [Internet]. 2021 Jan 1 [cited 2022 Jun 7];10(1). Available from:  
517 <https://pubmed.ncbi.nlm.nih.gov/35062723/>
- 518 23. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020  
519 statement: an updated guideline for reporting systematic reviews. *BMJ* [Internet]. 2021 Mar 29  
520 [cited 2022 Jun 7];372. Available from: <https://pubmed.ncbi.nlm.nih.gov/33782057/>
- 521 24. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for  
522 assessing risk of bias in non-randomised studies of interventions. *BMJ* [Internet]. 2016 Oct 12 [cited  
523 2022 Jun 7];355. Available from: <https://www.bmj.com/content/355/bmj.i4919>
- 524 25. Viechtbauer W. Bias and efficiency of meta-analytic variance estimators in the random-effects  
525 model. *Journal of Educational and Behavioral Statistics*. 2005;30(3):261–93.
- 526 26. Cochran WG. The Combination of Estimates from Different Experiments. *Biometrics* [Internet]. 1954  
527 Mar [cited 2022 Jun 7];10(1):101. Available from: </record/1955-00087-001>
- 528 27. Higgins JPT, Thompson SG. Controlling the risk of spurious findings from meta-regression. *Stat Med*  
529 [Internet]. 2004 Jun 15 [cited 2022 Jun 7];23(11):1663–82. Available from:  
530 <https://pubmed.ncbi.nlm.nih.gov/15160401/>
- 531 28. Viechtbauer W, Cheung MWL. Outlier and influence diagnostics for meta-analysis. *Res Synth*  
532 *Methods* [Internet]. 2010 Apr [cited 2022 Jun 7];1(2):112–25. Available from:  
533 <https://pubmed.ncbi.nlm.nih.gov/26061377/>
- 534 29. Begg CB, Mazumdar M. Operating Characteristics of a Rank Correlation Test for Publication Bias.  
535 *Biometrics*. 1994 Dec;50(4):1088.
- 536 30. Sterne JAC, Egger M. Regression methods to detect publication and other bias in meta-analysis.  
537 *Publication Bias in Meta-Analysis: Prevention, Assessment and Adjustments*. 2006 Jan 1;99–110.
- 538 31. Spensley KJ, Gleeson S, Martin P, Thomson T, Clarke CL, Pickard G, et al. Comparison of Vaccine  
539 Effectiveness Against the Omicron (B.1.1.529) Variant in Hemodialysis Patients. *Kidney Int Rep*  
540 [Internet]. 2022 Apr [cited 2022 Jun 7];7(6). Available from:  
541 <https://pubmed.ncbi.nlm.nih.gov/35434428/>
- 542 32. Gray MBBCH GE, Collie S, Garrett MBBS N, Goga A, Champion J, Zylstra M, et al. Vaccine  
543 effectiveness against hospital admission in South African health care workers who received a  
544 homologous booster of Ad26.COVID during an Omicron COVID19 wave: Preliminary Results of the  
545 Sisonke 2 Study. *medRxiv* [Internet]. 2021 Dec 29 [cited 2022 Jun 7];2021.12.28.21268436. Available  
546 from: <https://www.medrxiv.org/content/10.1101/2021.12.28.21268436v1>
- 547 33. Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, Tian Y, et al. Effectiveness of mRNA-1273 against  
548 SARS-CoV-2 Omicron and Delta variants. *Nat Med* [Internet]. 2022 May 1 [cited 2022 Jun 7];28(5).  
549 Available from: <https://pubmed.ncbi.nlm.nih.gov/35189624/>
- 550 34. Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, et al. Association Between 3  
551 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron  
552 and Delta Variants. *JAMA* [Internet]. 2022 Feb 15 [cited 2022 Jun 7];327(7):639–51. Available from:  
553 <https://pubmed.ncbi.nlm.nih.gov/35060999/>
- 554 35. Andeweg SP, Gier B de, Eggink D, Ende C van den, Maarseveen N van, Ali L, et al. Protection of  
555 COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2



- 556 infections. medRxiv [Internet]. 2022 May 12 [cited 2022 Jun 7];2022.02.06.22270457. Available  
557 from: <https://www.medrxiv.org/content/10.1101/2022.02.06.22270457v3>
- 558 36. Chemaitelly H, Tang P, Hasan MR, AlMukdad S, Yassine HM, Benslimane FM, et al. Waning of  
559 BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. *New England Journal of*  
560 *Medicine* [Internet]. 2021 Dec 9 [cited 2022 Jun 7];385(24):e83. Available from:  
561 <https://www.nejm.org/doi/full/10.1056/NEJMoa2114114>
- 562 37. Powell AA, Kirsebom F, Stowe J, McOwat K, Saliba V, Ramsay ME, et al. Adolescent vaccination with  
563 BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine and effectiveness of the first dose against COVID-  
564 19: national test-negative case-control study, England. medRxiv [Internet]. 2021 Dec 11 [cited 2022  
565 Jun 7];2021.12.10.21267408. Available from:  
566 <https://www.medrxiv.org/content/10.1101/2021.12.10.21267408v1>
- 567 38. Sheikh A, Kerr S, Woolhouse M, McMenamin J, Robertson C. Severity of Omicron variant of concern  
568 and vaccine effectiveness against symptomatic disease: national cohort with nested test negative  
569 design study in Scotland. G. Balint, Antala B, Carty C, Mabieme JMA, Amar IB, Kaplanova A, editors.  
570 *Uniwersytet śląski* [Internet]. 2013 [cited 2022 Jun 7];343–54. Available from:  
571 <https://sbc.org.pl/dlibra/publication/99008/edition/93276/synteza-i-aktywnosc-biologicznawych-analogow-tiosemikarbazonowych-chelatorow-zelaza-serda-maciej?language=en>  
572
- 573 39. Collie S, Champion J, Moultrie H, Bekker LG, Gray G. Effectiveness of BNT162b2 Vaccine against  
574 Omicron Variant in South Africa. *New England Journal of Medicine* [Internet]. 2022 Feb 3 [cited 2022  
575 Jun 8];386(5):494–6. Available from: <https://www.nejm.org/doi/full/10.1056/NEJMc2119270>
- 576 40. Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al. Waning 2-Dose and 3-Dose  
577 Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent  
578 Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant  
579 Predominance — VISION Network, 10 States, August 2021–January 2022. *MMWR Morbidity and*  
580 *Mortality Weekly Report* [Internet]. 2022 [cited 2022 Jun 8];71(7):255–63. Available from:  
581 <https://www.cdc.gov/mmwr/volumes/71/wr/mm7107e2.htm>
- 582 41. Tartof SY, Slezak JM, Puzniak L, Hong V, Xie F, Ackerson BK, et al. BNT162b2 (Pfizer–Biontech) mRNA  
583 COVID-19 Vaccine Against Omicron-Related Hospital and Emergency Department Admission in a  
584 Large US Health System: A Test-Negative Design. *SSRN Electronic Journal* [Internet]. 2022 Jan 20  
585 [cited 2022 Jun 8]; Available from: <https://papers.ssrn.com/abstract=4011905>
- 586 42. Thompson MG, Natarajan K, Irving SA, Rowley EA, Griggs EP, Gaglani M, et al. Effectiveness of a  
587 Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent  
588 Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant  
589 Predominance — VISION Network, 10 States, August 2021–January 2022. *MMWR Morbidity and*  
590 *Mortality Weekly Report* [Internet]. 2022 Jan 21 [cited 2022 Jun 8];71(4):139–45. Available from:  
591 <https://www.cdc.gov/mmwr/volumes/71/wr/mm7104e3.htm>
- 592 43. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the  
593 BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* [Internet]. 2020 Dec 31 [cited 2022 Jun  
594 8];383(27):2603–15. Available from: <https://pubmed.ncbi.nlm.nih.gov/33301246/>
- 595 44. Baden LR, el Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-  
596 1273 SARS-CoV-2 Vaccine. *New England Journal of Medicine*. 2021 Feb 4;384(5):403–16.
- 597 45. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and Efficacy of  
598 Single-Dose Ad26.COV2.S Vaccine against Covid-19. *New England Journal of Medicine* [Internet].



599 2021 Jun 10 [cited 2022 Jun 8];384(23):2187–201. Available from:  
600 <https://www.nejm.org/doi/full/10.1056/NEJMoa2101544>

601 46. Lin DY, Gu Y, Wheeler B, Young H, Holloway S, Sunny SK, et al. Effectiveness of Covid-19 Vaccines in  
602 the United States Over 9 Months: Surveillance Data from the State of North Carolina. medRxiv  
603 [Internet]. 2021 Oct 26 [cited 2022 Jun 8];2021.10.25.21265304. Available from:  
604 <https://www.medrxiv.org/content/10.1101/2021.10.25.21265304v1>

605